Nuclear protein of the testis midline carcinoma of the thorax. (23rd March 2022)

• Record Type: Journal Article
• Authors: Saiki, Ayae; Sakamoto, Keita; Bee, Yuan; Izumo, Takehiro
• Is Part Of: Japanese journal of clinical oncology. Volume 52:Number 6(2022)
• Page Start: 531
• Page End: 538
• Publication Date: 2022-03-23
• Subjects: Oncology -- Periodicals; Cancer -- Periodicals; 616.994005
• DOI: 10.1093/jjco/hyac033
• Languages: English
• ISSNs: 0368-2811

Abstract

Abstract: Nuclear protein of the testis (NUT) midline carcinoma (NMC) is a rare tumor that typically presents in the head, neck, and chest region. NMC is characterized by rearrangement of the NUTM1 gene. It mainly affects children and young adults and is rapidly progressive and lethal. Reportedly, the prognoses of NMCs of the head and neck improve following aggressive initial surgical resection +/− postoperative chemoradiotherapy (CRT) or radiotherapy (RT). However, as NMC of the thorax was identified later, treatments to improve its prognosis are yet to be identified. Our review reveals that NMC is an extremely rare cancer, and most patients remain undiagnosed. Furthermore, this review outlines the clinical characteristics of NMC of the thorax and the prospects for its treatment.